ArticleJournal of the American Society of Nephrology : JASN2019
National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.
Article in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07341516 (Worldwide Assessment of Deceased Donor Kidney Utilization), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Worldwide Assessment of Deceased Donor Kidney Utilization: Disparities, Temporal Trends, and Outcomes
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.Journal of the American Society of Nephrology : JASN · 2020Trial
- Consent to Receive Offers for Kidneys From Donors With Hepatitis C Among Pediatric Kidney Transplant Candidates in the United States.Pediatric transplantation · 2025Article
- Dare to HOPE: a step closer to HIVNature reviews. Nephrology · 2025Article
- Risk of Cytomegalovirus Viremia Following Transplantation of Hepatitis C-Viremic Donor Kidneys Into Uninfected Recipients: A Multi-Center Retrospective Cohort Study.Transplant infectious disease : an official journal of the Transplantation Society · 2025Article
- Real-world experience in treatment of donor-derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Center and Individual Willingness to Consider Heart and Lung Offers From Donors With Hepatitis C.The Journal of surgical research · 2024Article
- Patient Perspectives on Solid Organ Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia.Open forum infectious diseases · 2024Article
- Twelve-month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease.Advances in kidney disease and health · 2023Review
- Characterization of Transplant Center Decisions to Allocate Kidneys to Candidates With Lower Waiting List Priority.JAMA network open · 2023Article
- Trends in use and three-year outcomes of hepatitis C virus-viremic donor lung transplants for hepatitis C virus-seronegative recipients.The Journal of thoracic and cardiovascular surgery · 2023Article
- The association of center volume with transplant outcomes in selected high-risk groups in kidney transplantation.BMC nephrology · 2023Article
- Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?Renal failure · 2022Review
- CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.Renal failure · 2022Article
- Decision-making Among Hepatitis C Virus-negative Transplant Candidates Offered Organs from Donors with HCV Infection.Transplantation direct · 2022Article
- One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.Kidney international reports · 2022Article
- Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.BioMed research international · 2022Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
backgroundRecent pilot trials have demonstrated the safety of transplanting HCV-viremic kidneys into HCV-seronegative recipients. However, it remains unclear if allograft function is impacted by donor HCV-viremia or recipient HCV-serostatus.
methodsWe used national United States registry data to examine trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019. We applied advanced matching methods to compare eGFR for similar kidneys transplanted into highly similar recipients of kidney transplants.
resultsOver time, HCV-seronegative recipients received a rising proportion of HCV-viremic kidneys. During the first quarter of 2019, 200 HCV-viremic kidneys were transplanted into HCV-seronegative recipients, versus 69 into HCV-seropositive recipients, while 105 HCV-viremic kidneys were discarded. The probability of HCV-viremic kidney discard has declined over time. Kidney transplant candidates willing to accept a HCV-seropositive kidney increased from 2936 to 16,809 from during this time period. When transplanted into HCV-seronegative recipients, HCV-viremic kidneys matched to HCV-non-viremic kidneys on predictors of organ quality, except HCV, had similar 1-year eGFR (66.3 versus 67.1 ml/min per 1.73 m
conclusionsBy 2019, HCV-seronegative patients received the majority of kidneys transplanted from HCV-viremic donors. Widely used organ quality scores underestimated the quality of HCV-viremic kidneys based on 1-year allograft function. Recipient HCV-serostatus was also not associated with worse short-term allograft function using HCV-viremic kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.